Oliver Dorigo, MD
Gynecological Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 37 years
- Graduated 1989
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dorigo’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A63220 · Current
Licensed to practise in California · since 1997 · expires 2027-05-31 · Ruprecht-Karls-University of Heidelberg Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$48,338
Medicare paid this office $48,338 for 140 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 30 | $7,227 | $122 |
| Short return visit (20+ min) | 58 | $4,306 | $54 |
| Return visit (30+ min) | 28 | $3,167 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,818 | $69 |
| New patient visit (60+ min) | 13 | $2,120 | $163 |
See all 9 services
| Return visit (30+ min) | 30 | $7,227 | $122 |
| Short return visit (20+ min) | 58 | $4,306 | $54 |
| Return visit (30+ min) | 28 | $3,167 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,818 | $69 |
| New patient visit (60+ min) | 13 | $2,120 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $2,093 | $110 |
| Short return visit (20+ min) | 20 | $2,025 | $75 |
| New patient visit (45+ min) | 17 | $1,918 | $113 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,452 | $44 |
Procedures Medicare counted
| Removal of the uterus | 16 | More than 90% of doctors who do this |
Who their Medicare patients are
140 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 22% · Health risk score 1.88. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 71% · Cancer 55% · Diabetes 28% · Coronary heart disease 21% · Chronic kidney disease 21% · Depression 21% · Atrial fibrillation 20% · Heart failure 14% · COPD 8%.
The office billed $325,019, Medicare allowed $62,326 and paid $48,338; for 395 services of 41 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 140 | 395 | 73 | 1.88 | $325,019 | $48,338 |
| 2023 | 140 | 367 | 72 | 1.73 | $303,572 | $52,290 |
| 2022 | 115 | 268 | 72 | 1.94 | $178,251 | $30,861 |
| 2021 | 139 | 491 | 72 | 2.06 | $378,464 | $59,161 |
| 2020 | 146 | 511 | 71 | 2.26 | $450,312 | $64,337 |
| 2019 | 155 | 440 | 71 | 2.03 | $362,337 | $68,277 |
| 2018 | 114 | 362 | 71 | 2.29 | $228,953 | $43,959 |
| 2017 | 115 | 393 | 71 | 1.96 | $422,245 | $65,775 |
| 2016 | 96 | 318 | 71 | 1.90 | $230,901 | $39,208 |
| 2015 | 72 | 184 | 72 | 1.93 | $187,582 | $30,908 |
| 2014 | 58 | 151 | 70 | 1.82 | $216,833 | $32,204 |
| 2013 | 78 | 133 | 71 | 1.66 | $95,721 | $17,523 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 40 | $5,410 | $89 |
| Short return visit (20+ min) | 66 | $5,110 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $3,502 | $73 |
| New patient visit (45+ min) | 17 | $2,087 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,674 | $120 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $1,219 | $45 |
2022: 3 services
| Short return visit (20+ min) | 63 | $4,503 | $52 |
| Return visit (30+ min) | 29 | $3,352 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,531 | $65 |
2021: 8 services
| Short return visit (20+ min) | 79 | $9,395 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $4,285 | $66 |
| Return visit (30+ min) | 23 | $3,311 | $92 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $2,442 | $35 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $2,036 | $127 |
| New patient visit (45+ min) | 16 | $1,896 | $118 |
| New patient visit (60+ min) | 11 | $1,891 | $172 |
| Short return visit | 19 | $397 | $21 |
2020: 9 services
| Return visit (30+ min) | 50 | $6,367 | $70 |
| Short return visit (20+ min) | 55 | $3,811 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,428 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $3,188 | $128 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 23 | $3,052 | $36 |
| New patient visit (45+ min) | 16 | $1,918 | $120 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,209 | $67 |
| Return visit (30+ min) | 16 | $1,200 | $71 |
| New patient visit (30+ min) | 13 | $915 | $70 |
2019: 6 services
| Return visit (30+ min) | 50 | $6,271 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $5,149 | $66 |
| Short return visit (20+ min) | 43 | $2,791 | $41 |
| New patient visit (60+ min) | 18 | $2,447 | $136 |
| New patient visit (45+ min) | 20 | $2,332 | $117 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,279 | $36 |
2018: 5 services
| Return visit (30+ min) | 46 | $5,245 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $5,230 | $65 |
| Short return visit (20+ min) | 36 | $2,305 | $41 |
| New patient visit (45+ min) | 20 | $2,190 | $110 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $874 | $35 |
2017: 8 services
| Return visit (30+ min) | 38 | $5,110 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $4,758 | $63 |
| New patient visit (60+ min) | 16 | $2,160 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,831 | $122 |
| New patient visit (45+ min) | 15 | $1,686 | $112 |
| Long return visit (40+ min) | 14 | $1,395 | $100 |
| Short return visit (20+ min) | 27 | $1,388 | $39 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $1,048 | $35 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $5,980 | $64 |
| Short return visit (20+ min) | 41 | $3,656 | $44 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,814 | $176 |
| New patient visit (45+ min) | 18 | $2,076 | $115 |
| New patient visit (60+ min) | 12 | $1,591 | $133 |
| Return visit (30+ min) | 16 | $1,589 | $66 |
2015: 4 services
| New patient visit (60+ min) | 19 | $2,847 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,311 | $64 |
| Return visit (30+ min) | 21 | $2,174 | $70 |
| Short return visit (20+ min) | 22 | $1,291 | $43 |
2014: 3 services
| Return visit (30+ min) | 23 | $2,867 | $70 |
| New patient visit (60+ min) | 19 | $2,842 | $150 |
| Short return visit (20+ min) | 12 | $682 | $43 |
2013: 2 services
| Return visit (30+ min) | 14 | $1,199 | $80 |
| Short return visit (20+ min) | 27 | $1,191 | $44 |
Medicaid work
$957 in 2024
Medicaid paid $957 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $957 |
| 2024 | 12 | 1 | 12 | $957 |
| 2023 | 13 | 1 | 12 | $397 |
| 2022 | 13 | 1 | 13 | $248 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 13 | $397 |
2022
| Short return visit (20+ min) | 13 | $248 |
Drugs they prescribed that Part D paid
$101,021
Pharmacies billed $101,021 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 35) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
21 generic and 14 brand-name prescriptions · $101,021 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 35 | 18 | 0% (0) | 40% | $101,021 |
| 2023 | 30 | 17 | 0% (0) | None | $826 |
| 2022 | 22 | None | 0% (0) | None | $585 |
| 2021 | 54 | 23 | None | None | $17,554 |
| 2020 | 80 | 25 | 0% (0) | 23% | $127,110 |
| 2019 | 64 | 30 | 0% (0) | None | $4,468 |
| 2018 | 102 | 37 | 0% (0) | 21% | $12,657 |
| 2017 | 124 | 45 | 0% (0) | 19% | $41,080 |
| 2016 | 68 | 23 | 0% (0) | None | $30,798 |
| 2015 | 77 | 27 | None | 14% | $67,974 |
| 2014 | 55 | 20 | None | None | $7,973 |
| 2013 | 44 | 18 | 0% (0) | None | $6,887 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 1 drug
| Imiquimod | 15 | $416 | $28 |
2020: 1 drug
| Imiquimod | 13 | $373 | $29 |
2019: 1 drug
| Enoxaparin | 11 | $2,939 | $267 |
2017: 1 drug
| Enoxaparin | 11 | $2,328 | $212 |
2015: 1 drug
| Letrozole | 13 | $129 | $10 |
2014: 1 drug
| Prochlorperazine Maleate | 12 | $72 | $6 |
Money from drug and device companies
$1,684 in 2025
| 2025 | 4 | 10 | $1,000 | $1,684 |
| 2024 | 4 | 10 | $2,070 | $5,025 |
| 2023 | 1 | 7 | $7,309 | $8,379 |
| 2022 | 2 | 3 | None | $70 |
| 2021 | 5 | 6 | $12,328 | $12,328 |
| 2020 | 2 | 8 | $8,472 | $8,472 |
| 2019 | 6 | 56 | $40,893 | $48,571 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eli Lilly and | None | $1,053 | 2 payments
|
| Abbvie | Elahere | $394 | 3 payments
|
| Medtronic | Signia | $183 | 4 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $54 | 1 payment
|
See all 10 published payments
| Intuitive Surgical | Meals · 2025-12-30 | Da Vinci Surgical System | $54 |
| Abbvie | Meals · 2025-12-11 | Elahere | $120 |
| Medtronic | Meals · 2025-11-20 | Ligasure | $7 |
| Medtronic | Meals · 2025-10-14 | Signia | $159 |
| Abbvie | Meals · 2025-08-18 | Elahere | $124 |
| Medtronic | Meals · 2025-08-05 | Ligasure | $11 |
| Eli Lilly and | Consulting · 2025-07-21 | None | $1,000 |
| Medtronic | Meals · 2025-07-15 | Ligasure | $7 |
| Eli Lilly and | Meals · 2025-06-01 | None | $53 |
| Abbvie | Meals · 2025-06-01 | Elahere | $150 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,025
| Intuitive Surgical | Da Vinci Surgical System | $2,500 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $1,477 | 3 payments
|
| ImmunoGen | Elahere | $825 | 2 payments
|
| Abbvie | Elahere | $223 | 3 payments
|
2023: $8,379
| ImmunoGen | Elahere | $8,379 | 7 payments
|
2022: $70
| Myriad Genetic Laboratories | Precisetumor | $45 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $25 | 1 payment
|
2021: $12,328
| AstraZeneca Pharmaceuticals LP | Lynparza | $5,823 | 2 payments
|
| Eisai | Lenvima | $1,875 | 1 payment
|
| Blueprint Medicines | None | $1,680 | 1 payment
|
| Merck Sharp & Dohme | None | $1,500 | 1 payment
|
| GlaxoSmithKline | Zejula | $1,450 | 1 payment
|
2020: $8,472
| AstraZeneca Pharmaceuticals LP | Lynparza | $4,484 | 3 payments
|
| GlaxoSmithKline | Zejula | $3,988 | 5 payments
|
2019: $48,571
| Tesaro | Zejula | $39,595 | 44 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $3,533 | 5 payments
|
| Clovis Oncology | Rubraca | $2,101 | 3 payments
|
| Merck Sharp & Dohme | None | $2,000 | 2 payments
|
| Genentech USA | Avastin | $1,330 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| EMD Serono, Inc. · A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During Or After Platinum-Containing Chemotherapy · 2021 | Their institution | $240,477 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer · 2022 | Their institution | $145,653 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized Study of Mln0128 A Dual Torc1-2 Inhibitor, Mln0128 + Mln1117 A Pi3ka Inhibitor, Weekly Paclitaxel, Or the Combination of Weekly Paclitaxel and Mln0128 in Women With Advanced, Recurrent, Or Persistent Endometrial Cancer · 2019 | Their institution | $51,084 |
| AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2022 | Their institution | $34,483 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2019 | Their institution | $32,898 |
| Acerta Pharma LLC · A Phase 2 Proof of Concept Study of Acp 196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2019 | Their institution | $26,640 |
| EMD Serono, Inc. · A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During Or After Platinum-Containing Chemotherapy · 2020 | Their institution | $24,640 |
| AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2021 | Their institution | $24,603 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) (Ariel2) · 2019 | Their institution | $21,403 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2020 | Their institution | $18,012 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Sapanisertib, Combination of Sapanisertib With Mln1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer · 2020 | Their institution | $17,088 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2020 | Their institution | $15,499 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2019 | Their institution | $12,928 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy · 2020 | Their institution | $6,170 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2021 | Their institution | $5,836 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2022 | Their institution | $5,678 |
| AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2023 | Their institution | $4,992 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer · 2023 | Their institution | $4,189 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy · 2019 | Their institution | $3,311 |
| AstraZeneca Pharmaceuticals LP · ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy"; · 2024 | Their institution | $1,611 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2021 | Their institution | $1,162 |
| Merck Sharp & Dohme Corporation · A Phase 2 Proof-of-Concept Study of Acp-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2021 | Their institution | $125 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1306873294
- Licence
- CA A63220California A63220: Current · expires 2027-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A632200
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207VE0102X (207VE0102X); Federal specialty code 207VX0000X (207VX0000X)
- Mailing address
- 5767 W Century Blvd, Suite 400, Los Angeles, CA, 90045
- NPI first listed
- 2006-06-27
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 200 Medical Plaza, Los Angeles, CA, 90095